0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > Integrin alpha V beta 8 > IT8-H52W4

Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein, His Tag&Tag Free

Order Now

  • Synonym
    Integrin alpha V beta 8,ITGAV&ITGB8
  • Source
    Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free(IT8-H52W4) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Glu 43 - Arg 684 (ITGB8) (Accession # NP_002201.1 (ITGAV) & NP_002205.1 (ITGB8)).
    Predicted N-terminus: Phe 31 (ITGAV) & Glu 43 (ITGB8)
  • Molecular Characterization
    Integrin alpha V beta 8 Structure

    Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free, produced by co-expression of ITGAV and ITGB8, has a calculated MW of 112.9 kDa (ITGAV) and 76.5 kDa (ITGB8). Subunit ITGAV is fused with polyhistidine tag at the C-terminus and followed by a acidic tail and subunit ITGB8 contains no tag but a basic tail at the C-terminus. The non-reducing (NR) protein migrates as 130-150 kDa (ITGAV) and 80-90 kDa (ITGB8) respectively due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM NaCl, pH8.0 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Integrin alpha V beta 8 SDS-PAGE

Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 Integrin alpha V beta 8 ELISA

Immobilized Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT8-H52W4) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Latent TGF-Beta 1, His,Avitag (Cat. No. TG1-H82Qb) with a linear range of 1-31 ng/mL (QC tested).

 Integrin alpha V beta 8 ELISA

Immobilized Human Fibronectin at 10 μg/mL (100 μL/well) can bind Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT8-H52W4) with a linear range of 0.313-10 μg/mL (Routinely tested).

 Integrin alpha V beta 8 ELISA

Immobilized Human Vitronectin at 5 μg/mL (100 μL/well) can bind Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT8-H52W4) with a linear range of 0.313-10 μg/mL (Routinely tested).

  • Background
    Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €410.00

Price(EUR) : €3200.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:2 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message